LinkOPH

NEW ORLEANS — A post-marketing safety evaluation thus far has been consistent with the pre-marketing clinical trial program for ocriplasmin, according to a speaker here. “At the most recent retina meeting, it became clear that there was significant concern among colleagues regarding post-marketing events surrounding ocriplasmin [Jetrea, ThromboGenics],” Paul Hahn, MD, PhD, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting. In response to that concern, the American Society of Retina Specialists convened a Therapeutic Surveillance Committee to compile post-marketing data.

Read more →

NEW ORLEANS — Comparative studies such as CATT, IVAN, MANTA, GEFAL, BRAMD and LUCAS have shown no clinically significant differences between ranibizumab and bevacizumab, a speaker said here. “There are no statistical differences between these small percentages. People keep trying to make it significant. It’s probably noise,” Daniel F. Martin, MD, chairman of the Cole Eye Institute, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Read more →

NEW ORLEANS — Parallel studies testing separate regimens of aflibercept injections against laser photocoagulation found both drug regimens to work better than laser photocoagulation in patients with diabetic macular edema.Reporting the primary results at 1 year of the VIVID and VISTA trials, Diana V. Do, MD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting, “Eyes that were randomized to either dosing regimen of aflibercept had superior visual acuity outcomes compared to laser-treated eyes.”

Read more →

NEW ORLEANS — Corneal cross-linking performed at a higher wattage for a shorter period of time produces identical results and may increase safety due to the abbreviated exposure for the patient, a speaker reported here. “While 3 mW/cm2 for 30 minutes won’t damage anything, it turns out that 3 mW/cm2 is the same as 30 mW/cm2, and it’s safe,” John Marshall, PhD, said at Refractive Surgery Subspecialty Day, which was jointly sponsored by the American Academy of Ophthalmology and the International Society of Refractive Surgery. “The shorter the exposure, the (Read more...)

Alphaeon announced that it acquired a U.S. license from Schwind eye-tech solutions to market the Amaris excimer laser system, according to a press release. Alphaeon, a wholly owned subsidiary of Strathspey Crown Holdings, will oversee the U.S. Food and…

Read more →

NEW ORLEANS — Long-term results of corneal collagen cross-linking proved promising, with few complications, a speaker said here. “Primary reports show that the complication rate was 0% to 10% and the rate of failure was also very small, 0% to 2%,” Theo Seiler, MD, PhD, said during Refractive Surgery Subspecialty Day preceding the American Academy of Ophthalmology meeting. “Cross-linking induces structural changes of the cornea that may go on for many years.” Failure rates were 1% at 1 year, 2% at 2 years and 0% at 4 years. Progression of (Read more...)